Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyAlaska Medicaid Naloxone Coverage & Prior Auth | O…
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Alaska Medicaid Pharmacy - Naloxone: point-of-sale edits and prior authorization

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Alaska Medicaid pharmacy claims processing edits and prior authorization requirements for naloxone products, and pharmacist actions when multiple Narcan® Nasal Spray fills occur; applies to Alaska Medicaid-enrolled beneficiaries and dispensing pharmacists.

    Policy Summary
    PayerAlaska Medicaid
    PolicyAlaska Medicaid Pharmacy - Naloxone: point-of-sale edits and prior authorization
    Policy CodePolicy N/A
    Change TypeCoverage and operational edits updated
    Effective DateSep 7, 2016
    Next Review DateN/A
    Key ActionWhen a patient requests a third Narcan® NS fill within 365 days, the pharmacist must contact prescribers, document the intervention, and may override with PATC = 5 after documenting.
    SourceLink
    POLICY UPDATE CHANGES

    Prior authorization requirement for Narcan® Nasal Spray (NS) was removed except in specific circumstances.

    A point-of-sale edit will reject claims for a patient's third Narcan® NS fill within a rolling 365-day period and requires pharmacist prescriber contact and documentation before override.

    Evzio® Auto-Injector requires step therapy prior authorization before payment will be considered.

    >=3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Narcan NS fills that trigger point-of-sale alert/reject
    3 daysMax follow-up time if prescriber unavailable
    PATC=5Override code after documented intervention
    Sep 7, 2016Edits effective date

    Naloxone Coverage and POS Rules

    Coverage and point-of-sale operational rules for naloxone products

    Covered when the following product-specific coverage and point-of-sale operational rules are met:

    ALL of the following

    • Narcan coverage

      • Narcan® Nasal Spray (NS) is designated the preferred agent for emergency treatment of opioid overdose and does not require prior authorization except in specific circumstances.
    • Evzio prior authorization

      • Evzio® Auto-Injector requires step therapy prior authorization before payment will be considered; follow Alaska DHSS online clinical criteria and submit the product-specific form.
    • Point-of-sale edit for Narcan NS

      • Claims for a patient’s third Narcan® NS fill within a rolling 365-day period will reject at point-of-sale with NCPDP reject 75 and the message: '>= 3 fills in 1 yr; contact MD, document on Rx, then override.'
      • When the edit rejects, the pharmacist must contact the Narcan prescriber and the opioid prescriber (if different) to notify them that the patient has used Narcan NS two or more times in the previous year and is requesting another fill.
      • The pharmacist must inquire what intervention the opioid prescriber intends, including any adjustments to the patient’s medication regimen to reduce overdose risk; the details of the conversation must be documented on the prescription (hard copy or electronic) including the prescriber’s office contacted, contact person, and date.
      • If the prescriber is not immediately available, the pharmacist may fill the Narcan NS prescription but must follow up with the prescriber within 3 days; prescriber response may be by phone or fax.
      • After documenting the intervention on the prescription, the pharmacist may override the point-of-sale denial using PATC = 5 (Prior Auth Type Code, NCPDP field 461-EU); documentation must be made available to Alaska Medicaid upon request.
    • Suggested prescriber interventions

      • Possible options include use of a non-opioid analgesic; decreasing opioid potency per pill; decreasing frequency of opioid administration; tapering off opioids; discontinuing opioids; and decreasing or discontinuing concomitant CNS depressants (e.g., benzodiazepines, alcohol).
    Documentation and auditability

    Point-of-Sale Edits and Billing Codes

    POS edit and override codesmixed
    75NCPDP reject code displayed at point-of-sale for >=3 fills in 1 year
    PATC=5Prior Auth Type Code used to override after documented intervention
    Narcan NS fill threshold — point-of-sale rule
    Threshold3 fills within a rolling 365-day period
    Point-of-sale reject codeNCPDP 75 (message: '>= 3 fills in 1 yr; contact MD, document on Rx, then override .')
    Required pharmacist actionContact Narcan prescriber and opioid prescriber, document intervention on the prescription (office, contact person, date)
    Override procedureAfter documenting intervention the pharmacist may override the POS reject
    ScopeApplies to Narcan® Nasal Spray (NS) fills under Alaska Medicaid

    Pharmacist and Prescriber Actions

    Prior Authorization

    Evzio step therapy prior authorization

    Evzio® Auto-Injector requires step therapy prior authorization before payment will be considered. Providers should refer to the Alaska DHSS pharmacy prior authorization web page for the product-specific clinical criteria and the form to submit.

    Documentation Required

    Narcan point-of-sale edit and required pharmacist actions

    Alaska Medicaid has a point-of-sale edit that will reject a claim (NCPDP reject 75) when a patient requests a third Narcan® Nasal Spray (NS) fill within a rolling 365-day period; the pharmacist must contact prescribers, document the intervention on the prescription, and may override using PATC = 5 after documentation. If the prescriber is not immediately available, the pharmacist may fill the Narcan NS but must follow up with the prescriber within 3 days.

    • POS reject: NCPDP reject 75 with message '>= 3 fills in 1 yr; contact MD, document on Rx, then override.'
    • Pharmacist must contact the Narcan prescriber and the opioid prescriber (if different) and document the intervention on the prescription, including office contacted, contact person, and date.

    Product Definitions

    Narcan® Nasal Spray (NS) — preferred agent and PA note
    Preferred agentNarcan® Nasal Spray (NS) is designated the preferred agent for emergency treatment of opioid overdose
    Prior authorization general ruleNarcan® NS will not require prior authorization except in specific circumstances
    Effective policy actionRemoval of routine prior authorization for Narcan® NS; exceptions remain as outlined in policy
    ApplicabilityApplies to Alaska Medicaid beneficiaries and dispensing pharmacists
    Evzio® Auto-Injector — step therapy prior authorization
    ProductEvzio® Auto-Injector
    Policy Summary
    PayerAlaska Medicaid
    PolicyAlaska Medicaid Pharmacy - Naloxone: point-of-sale edits and prior authorization
    Policy CodePolicy N/A
    Change TypeCoverage and operational edits updated
    Effective DateSep 7, 2016
    Next Review DateN/A
    Key ActionWhen a patient requests a third Narcan® NS fill within 365 days, the pharmacist must contact prescribers, document the intervention, and may override with PATC = 5 after documenting.
    SourceLink
    On This Page
    Naloxone Coverage and POS RulesPoint-of-Sale Edits and Billing CodesPharmacist and Prescriber ActionsProduct Definitions
  1. After documenting the intervention on the prescription, pharmacist may override the POS denial using PATC = 5 (Prior Auth Type Code, NCPDP field 461-EU).
  2. If prescriber not immediately available, pharmacist may dispense and must follow up within 3 days; documentation must be made available to Alaska Medicaid upon request.
  3. Authorization requirement
    Requires step therapy prior authorization before payment will be considered
    Where to find criteriaSee Alaska DHSS pharmacy prior authorization page for product-specific clinical criteria and form (http://dhss.alaska.gov/dhcs/pages/pharmacy/medpriorauthoriz.aspx)
    ImplicationClaims for Evzio will be subject to PA review and payment contingent on meeting step therapy criteria